

<https://helda.helsinki.fi>

---

## Metatranscriptomic assessment of burn wound infection clearance

Ojala, Teija

2021-01-01

---

Ojala , T , Lindford , A , Savijoki , K , Lagus , H M , Tommila , J , Medlar , A , Kuusela , P I , Varmanen , P , Holm , L , Vuola , J , Kankuri , E & Kankainen , M 2021 , ' Metatranscriptomic assessment of burn wound infection clearance ' , Clinical Microbiology and Infection , vol. 27 , no. 1 , pp. 144-146 . <https://doi.org/10.1016/j.cmi.2020.07.021>

---

<http://hdl.handle.net/10138/337789>

<https://doi.org/10.1016/j.cmi.2020.07.021>

---

cc\_by\_nc\_nd

acceptedVersion

---

*Downloaded from Helda, University of Helsinki institutional repository.*

*This is an electronic reprint of the original article.*


*This reprint may differ from the original in pagination and typographic detail.*

*Please cite the original version.*

# Journal Pre-proof

Metatranscriptomic assessment of burn wound infection clearance

Teija Ojala, Andrew Lindford, Kirsi Savijoki, Heli Lagus, Jenni Tommila, Alan Medlar, Pentti Kuusela, Pekka Varmanen, Liisa Holm, Jyrki Vuola, Esko Kankuri, Matti Kankainen



PII: S1198-743X(20)30428-6

DOI: <https://doi.org/10.1016/j.cmi.2020.07.021>

Reference: CMI 2147

To appear in: *Clinical Microbiology and Infection*

Received Date: 6 March 2020

Revised Date: 22 June 2020

Accepted Date: 16 July 2020

Please cite this article as: Ojala T, Lindford A, Savijoki K, Lagus H, Tommila J, Medlar A, Kuusela P, Varmanen P, Holm L, Vuola J, Kankuri E, Kankainen M, Metatranscriptomic assessment of burn wound infection clearance, *Clinical Microbiology and Infection*, <https://doi.org/10.1016/j.cmi.2020.07.021>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

**Title: Metatranscriptomic Assessment of Burn Wound Infection Clearance**

**Authors:** Teija Ojala<sup>1</sup>, Andrew Lindford<sup>2</sup>, Kirsi Savijoki<sup>3</sup>, Heli Lagus<sup>2</sup>, Jenni Tommila<sup>1</sup>, Alan Medlar<sup>4</sup>, Pentti Kuusela<sup>5</sup>, Pekka Varmanen<sup>3</sup>, Liisa Holm<sup>4</sup>, Jyrki Vuola<sup>2</sup>, Esko Kankuri<sup>1\*</sup>, Matti Kankainen<sup>6,7\*</sup>

**Author Affiliations:** <sup>1</sup>Department of Pharmacology, University of Helsinki, Helsinki, Finland; <sup>2</sup>Department of Plastic Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; <sup>3</sup>Department of Food and Nutrition, University of Helsinki, Helsinki, Finland; <sup>4</sup>Institute of Biotechnology, University of Helsinki, Helsinki, Finland; <sup>5</sup>Department of Bacteriology and Immunology, Haartman Institute, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland; <sup>6</sup>Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; <sup>7</sup>Translational Immunology Research Program and Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland

\*These authors contributed equally to this manuscript.

**Intended category:** Letter

**Keywords:** Wound infection; Wound healing; Treatment response assessment, Metatranscriptomics; 16S-profiling

**Running title:** Metatranscriptomics in treatment evaluation

**Address for correspondence:** Matti Kankainen, Research Programs Unit, Faculty of Medicine, P.O. Box 63, FIN-00014 University of Helsinki, Finland; email: matti.kankainen@helsinki.fi; phone: +358505636960, fax: +358947171897

*To the Editor,*

Skin and soft tissue infections are frequent infections in healthcare that vary in presentation and severity. The severe forms often require surgical intervention and antimicrobial therapy and their recovery should be assessed frequently to catch treatment failures [1]. Here, we used random sequencing of coding bacterial RNA (metatranscriptomics) and 16S rRNA-gene amplicon sequencing (16S-profiling) to characterise the post-treatment bacterial communities of a complicated burn wound and assess infection clearance.

A 2-year-old female sustained a ~5% total body surface area boiling water burn injury on the left side of her head and right arm. After initial conservative treatment by silver dressings, the healing was complicated by prolonged and persistent infections (**Fig. 1A**). During the course of the treatment, the patient underwent conventional microbiological testing, several antibiotic treatments, and multiple surgical debridements and skin graftings. The last adjustment of antibiotics occurred on day 96 (a switch to intravenous levofloxacin) and the last grafting operation three days later. Healing progressed and the wound was cured by day 147.

The post-treatment tissue samples (wound) for metatranscriptomics and 16S-profiling were extracted during the last grafting operation. Body site-matched, non-infected tissue was obtained from an independent patient and control samples with (spike-in) and without (normal) added *Staphylococcus epidermidis* ATCC 12228 were prepared. The metatranscriptomics workflow is outlined in **Figure 1B** and involved depletion of rRNAs and poly-adenylated-transcripts to enrich bacterial mRNAs. Illumina HiSeq (PE100) was used in sequencing. Data analysis followed our previous protocol [2] and employed an in-house built genome and gene sequence classification

databases (**Fig. 1C**). For 16S-profiling, DNA was extracted, V3-V4 region of 16S rRNA gene amplified, and amplicons sequenced using Illumina MiSeq (PE250). Reads were classified to species level. The detailed methodology is provided in the Supplementary text. The Operative Ethics Committee of the Hospital District for Helsinki and Uusimaa approved the study protocol (HUS 2076/2016). Written informed consent was obtained from all participants or their guardians.

Metatranscriptomics and 16S-profiling analyses both revealed samples to contain bacterial reads in varying portions (**Fig. 1D**). To account the variation, samples were sequenced to different total depths in both technologies.

A genus-level classification was assigned to 99.25% of metatranscriptomic (with an estimated precision of 0.94 and recall of 0.96; **Table S1**) and 99.99% of 16S-profiling bacterial reads. The identified major genera are listed in **Figures 1E** and **S1**. Correlation analysis revealed that genus-level abundancies correlated well across technologies in spike-in ( $r=0.95$ ) and normal ( $r=0.87$ ) but not in wound ( $r=-0.46$ ; **Fig. S2**). A strong correlation was also identified in metatranscriptomics between wound and normal ( $r=0.86$ ), while these were negatively associated in 16S-profiling ( $r=-0.89$ , **Fig. S2**). Diversity analyses corroborated the trends observed in the correlation analysis and highlighted the highest diversities for wound samples (**Fig. 1F**, **Fig. S3-S4**).

Differential abundance analysis revealed eight genera enriched between wound and normal by either technology (**Fig. 1G**, **Fig. S5**, **Table S2**). The skin commensal *Cutibacterium* was underrepresented in wound compared to normal. Genera enriched in wound harboured clinically associated pathogens, established 16S-profiling contaminants, and environmental bacteria unlikely to exist in the sample. Clinically associated *Micrococcus*, *Dietzia*, and *Corynebacterium* were highly enriched especially in 16S-profiling. The species-level results agreed with genus-level findings and revealed enrichment of specific *Micrococcus*, *Corynebacterium*, and *Dietzia* species by 16S-profiling (**Fig. S6-S7**, **Table S3**).

Examination of microbial gene activity at the UniRef90-level (with an estimated precision of 0.95 and recall of 0.83; **Table S1**) revealed activity of 594 (normal), 960 (wound), and 5,325 (spike-in) bacterial protein groups with  $\geq 2.5$  counts per million reads. The genes expressed in wound were mostly involved in basic cellular activities. Pathway enrichment analysis revealed no functional differences (**Fig. 1H, Tables S4 and S5**).

Metatranscriptomics is an interesting approach to assess treatment success. In this study, it revealed marked similarity between bacterial communities of post-treatment and normal samples and captured activity of normal cellular processes in wound; results which indicate infection clearance and agree with the clinical picture. The 16S-profiling in contrast supported the presence of an abnormal community and indicated marked enrichment of *Corynebacterium tuberculostearicum* associated to wound infections in patients with a long history of antibiotics [3] and an infection-associated and often misdiagnosed *Dietzia cinnamea* sensitive to levofloxacin [4]. Technical differences are unlikely to explain these discrepancies given the high cross-platform concordance among controls. Instead, the inability of DNA-amplicon-based approaches to differentiate the live and dead [5] might explain the differences, especially as microbiological cultures taken four days earlier listed coagulase-negative staphylococci and diphtheroids without detailing the species and were thereby partly in agreement with the 16S-profiling results unveiling unenriched levels of *Staphylococcus* and enriched levels of *Corynebacterium* in wound.

To conclude, this study demonstrated the value of metatranscriptomics in understanding rapid microbial alterations in complex host-microbe samples. Its use in infection clearance assessment warrants further investigations.

### **Transparency declaration**

The authors declare no conflicts of interest related to the study. This work was supported by the Academy of Finland [grant numbers 292635, 292589, 292646, 292626, and 292605]; Business

Finland [grant number 6113/31/2016]; and Finnish Cultural Foundation. Some of the results of this study were presented as an oral presentation at the 28<sup>th</sup> ECCMID, May 2018, Madrid, Spain.

### **Acknowledgments**

We thank the patients for their participation to this study; research nurses Päivi Nurmi and Hanna Lepoaho for help in data collection and patient recruitment; and Biomedicum Functional Genomics Unit and FIMM Sequencing Laboratory, University of Helsinki, for sequencing services. Processed genomic data are available on the Haematology Research Unit Helsinki web site (<http://hruh-20.it.helsinki.fi/bugsy>) and sequencing read data from the corresponding authors upon a reasonable request.

### **Appendix A. Supplementary data**

Supplementary data to this article can be found online at xxx.

### **References:**

1. Nathwani D, Dryden M, Garau J. Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe. *Int J Antimicrob Agents* **2016**; 48(2): 127-36.
2. Hanif T, Dhaygude K, Kankainen M, et al. Birch pollen allergen immunotherapy reprograms nasal epithelial transcriptome and recovers microbial diversity. *J Allergy Clin Immunol* **2019**.
3. Hinic V, Lang C, Weisser M, Straub C, Frei R, Goldenberger D. *Corynebacterium tuberculostearicum*: a potentially misidentified and multiresistant *Corynebacterium* species isolated from clinical specimens. *J Clin Microbiol* **2012**; 50(8): 2561-7.

4. Hirvonen JJ, Lepisto I, Mero S, Kaukoranta SS. First isolation of *Dietzia cinnamomea* from a dog bite wound in an adult patient. *J Clin Microbiol* **2012**; 50(12): 4163-5.
5. Josephson KL, Gerba CP, Pepper IL. Polymerase chain reaction detection of nonviable bacterial pathogens. *Appl Environ Microbiol* **1993**; 59(10): 3513-5.

### Figure legend:

**Fig 1. A: Clinical course of the patient.** The timeline illustrates admissions, antimicrobial medications, and results of standard microbial diagnostics from injury to recovery. Study samples were taken 3-days after a switch from the oral trimethoprim and sulphasalazine to the intravenous levofloxacin at post-injury day 99 during a grafting operation. **B: Metatranscriptomics sample processing and data analysis workflow.** Samples were immersed in transcriptome preserving reagent immediately upon extraction, tissue structure and cells were disrupted, total RNA was extracted and DNase treated, and bacterial mRNA was enriched by depleting rRNAs and polyadenylated-transcripts. **C: Gene classification scheme.** The reads were aligned against all known bacterial, archaeal, and viral coding sequences that were organized into sequence clusters in the presence of UniRef information as well as to human and technical sequences. Reads classified to human and technical references were ignored in analyses. **D: Read survival in metatranscriptomics and 16S-profiling.** For each sample, the stacked columns depict the portions of reads classified as bacterial (grey), classified ambiguously as bacterial and non-bacterial (cyan), classified solely as non-bacterial (blue), passing preprocessing but not classified (light blue), and failed in preprocessing (brown). The total number of reads (black) and the number of bacterial reads (grey) in millions are given above columns. **E: Relative distribution of bacterial genera.** Only genera accounting >5% of the bacterial reads in any samples by either metatranscriptomics (MetaTRS) or 16S-profiling (16S) are shown. Reads assigned to other genera are marked as 'other



genera'. Bacterial reads without genus-level classifications are marked as 'other Bacteria'. Both technologies correctly identified the spiked-in *Staphylococcus* as the major genera in the spike-in sample and reported the normal skin commensal *Cutibacterium* in the normal sample. **F: Bacterial beta-diversity.** Bray-Curtis dissimilarity-based principal coordinates analysis at the genus level revealed a high similarity between control samples assessed with different platforms. Wound samples assessed with different platforms were more dissimilar. **G: Enriched genera in wound versus normal.** The bar graph depicts fold change ( $\log_{10}$ ) of the enriched genera in wound versus normal. The difference between fold changes determined by 16S-profiling and metatranscriptomics are given above columns. Small values mark taxa likely related to inter-sample variance. High values represent taxa likely associated with the treatment response. Asterisks highlight genera accounting  $\geq 5\%$  of the total bacterial read count and with  $\geq 2$ -fold-change. Double asterisks highlight genera accounting  $\geq 5\%$  of the total bacterial read count and with  $\geq 5$ -fold-change. Conservative cut-offs were used to avoid false findings. **H: Pathways in wound and normal.** Pathways with  $\geq 10$  UniRef90-level assignments in wound and normal are listed. For each pathway, shown are the number of assignments to the given pathway, number of assignments to any pathway, and the Bonferroni corrected  $p$ -value of Chi-squared test between expected and observed frequencies. Example of the glycolysis pathway is detailed in the figure. Blue, red, and purple colours indicate functions supported by  $\geq 2.5$  counts per million bacterial reads in wound, normal, or both, respectively.

